NEJM:多支血管PCI的完全血运重建治疗心肌梗死效果分析(COMPLETE研究)

2019-10-10 xing.T MedSci原创

由此可见,在STEMI和多支冠状动脉疾病患者中,完全血运重建在减少心血管死亡或心肌梗塞风险以及心血管死亡、心肌梗塞或缺血性血运重建的风险方面优于仅罪犯病变的PCI。

在ST段抬高型心肌梗死(STEMI)患者中,罪犯病变的经皮冠状动脉介入治疗(PCI)降低了心血管死亡或心肌梗塞的风险。然而非罪犯病变的PCI是否可进一步降低发生此类事件的风险尚不清楚。

近日,顶级医学期刊NEJM上发表了一篇研究文章,研究人员将已经成功完成罪犯病变PCI的STEMI和多支冠状动脉疾病患者随机分配对血管造影中非罪犯病变进行PCI的完全血运重建的策略或未进行进一步血运重建。根据非罪犯病变PCI的预期时机(在住院期间或之后)进行随机分组。该研究的第一项主要结局是心血管死亡或心肌梗塞的综合症状;第二项主要结局是心血管死亡、心肌梗塞或缺血性血运重建的综合结局。

中位随访时间为3年,完全血运重建组2016例受试者中有158例患者(7.8%)发生了第一项主要结局,而仅罪犯病变PCI组中2025例患者有213例(10.5%)发生了第一项主要结局(风险比为0.74; 95%置信区间[CI]为0.60至0.91;P=0.004)。完全血运重建组中有179例患者(8.9%)发生了第二项主要结局,而仅罪犯病变PCI组中有339例患者(16.7%)(风险比为0.51;95%CI为0.43至0.61);P<0.001)。对于这两种主要的结局,无论非病灶性PCI的预期时机如何,始终可观察到完全血运重建的益处(对于第一项和第二项主要结局的相互作用P=0.62和P=0.27)。

由此可见,在STEMI和多支冠状动脉疾病患者中,完全血运重建在减少心血管死亡或心肌梗塞风险以及心血管死亡、心肌梗塞或缺血性血运重建的风险方面优于仅罪犯病变的PCI。 

原始出处:

Shamir R. Mehta,et al.Complete Revascularization with Multivessel PCI for Myocardial Infarction.NEJM.2019.https://www.nejm.org/doi/full/10.1056/NEJMoa1907775

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1910996, encodeId=d19c1910996df, content=<a href='/topic/show?id=e6045e517dd' target=_blank style='color:#2F92EE;'>#效果分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57517, encryptionId=e6045e517dd, topicName=效果分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Nov 21 13:59:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981252, encodeId=603d198125225, content=<a href='/topic/show?id=ab0e458e711' target=_blank style='color:#2F92EE;'>#完全血运重建#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45877, encryptionId=ab0e458e711, topicName=完全血运重建)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Sep 24 09:59:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060936, encodeId=448c20609368d, content=<a href='/topic/show?id=fa39432e08b' target=_blank style='color:#2F92EE;'>#多支血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43270, encryptionId=fa39432e08b, topicName=多支血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Jan 13 01:59:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035660, encodeId=47162035660b1, content=<a href='/topic/show?id=a378432e1e7' target=_blank style='color:#2F92EE;'>#多支血管PCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43271, encryptionId=a378432e1e7, topicName=多支血管PCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Thu Feb 20 22:59:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752049, encodeId=ccbc1e52049f9, content=<a href='/topic/show?id=6b2d5033f5' target=_blank style='color:#2F92EE;'>#complete#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5033, encryptionId=6b2d5033f5, topicName=complete)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=124036431900, createdName=lg.zhao, createdTime=Mon Feb 17 05:59:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773294, encodeId=23c61e7329455, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Thu Dec 12 06:59:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034976, encodeId=104810349e6cf, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Oct 10 10:59:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046926, encodeId=c2ae10469261f, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Thu Oct 10 10:59:00 CST 2019, time=2019-10-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1910996, encodeId=d19c1910996df, content=<a href='/topic/show?id=e6045e517dd' target=_blank style='color:#2F92EE;'>#效果分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57517, encryptionId=e6045e517dd, topicName=效果分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Nov 21 13:59:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981252, encodeId=603d198125225, content=<a href='/topic/show?id=ab0e458e711' target=_blank style='color:#2F92EE;'>#完全血运重建#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45877, encryptionId=ab0e458e711, topicName=完全血运重建)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Sep 24 09:59:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060936, encodeId=448c20609368d, content=<a href='/topic/show?id=fa39432e08b' target=_blank style='color:#2F92EE;'>#多支血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43270, encryptionId=fa39432e08b, topicName=多支血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Jan 13 01:59:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035660, encodeId=47162035660b1, content=<a href='/topic/show?id=a378432e1e7' target=_blank style='color:#2F92EE;'>#多支血管PCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43271, encryptionId=a378432e1e7, topicName=多支血管PCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Thu Feb 20 22:59:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752049, encodeId=ccbc1e52049f9, content=<a href='/topic/show?id=6b2d5033f5' target=_blank style='color:#2F92EE;'>#complete#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5033, encryptionId=6b2d5033f5, topicName=complete)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=124036431900, createdName=lg.zhao, createdTime=Mon Feb 17 05:59:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773294, encodeId=23c61e7329455, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Thu Dec 12 06:59:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034976, encodeId=104810349e6cf, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Oct 10 10:59:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046926, encodeId=c2ae10469261f, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Thu Oct 10 10:59:00 CST 2019, time=2019-10-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1910996, encodeId=d19c1910996df, content=<a href='/topic/show?id=e6045e517dd' target=_blank style='color:#2F92EE;'>#效果分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57517, encryptionId=e6045e517dd, topicName=效果分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Nov 21 13:59:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981252, encodeId=603d198125225, content=<a href='/topic/show?id=ab0e458e711' target=_blank style='color:#2F92EE;'>#完全血运重建#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45877, encryptionId=ab0e458e711, topicName=完全血运重建)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Sep 24 09:59:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060936, encodeId=448c20609368d, content=<a href='/topic/show?id=fa39432e08b' target=_blank style='color:#2F92EE;'>#多支血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43270, encryptionId=fa39432e08b, topicName=多支血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Jan 13 01:59:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035660, encodeId=47162035660b1, content=<a href='/topic/show?id=a378432e1e7' target=_blank style='color:#2F92EE;'>#多支血管PCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43271, encryptionId=a378432e1e7, topicName=多支血管PCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Thu Feb 20 22:59:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752049, encodeId=ccbc1e52049f9, content=<a href='/topic/show?id=6b2d5033f5' target=_blank style='color:#2F92EE;'>#complete#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5033, encryptionId=6b2d5033f5, topicName=complete)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=124036431900, createdName=lg.zhao, createdTime=Mon Feb 17 05:59:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773294, encodeId=23c61e7329455, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Thu Dec 12 06:59:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034976, encodeId=104810349e6cf, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Oct 10 10:59:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046926, encodeId=c2ae10469261f, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Thu Oct 10 10:59:00 CST 2019, time=2019-10-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1910996, encodeId=d19c1910996df, content=<a href='/topic/show?id=e6045e517dd' target=_blank style='color:#2F92EE;'>#效果分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57517, encryptionId=e6045e517dd, topicName=效果分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Nov 21 13:59:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981252, encodeId=603d198125225, content=<a href='/topic/show?id=ab0e458e711' target=_blank style='color:#2F92EE;'>#完全血运重建#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45877, encryptionId=ab0e458e711, topicName=完全血运重建)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Sep 24 09:59:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060936, encodeId=448c20609368d, content=<a href='/topic/show?id=fa39432e08b' target=_blank style='color:#2F92EE;'>#多支血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43270, encryptionId=fa39432e08b, topicName=多支血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Jan 13 01:59:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035660, encodeId=47162035660b1, content=<a href='/topic/show?id=a378432e1e7' target=_blank style='color:#2F92EE;'>#多支血管PCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43271, encryptionId=a378432e1e7, topicName=多支血管PCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Thu Feb 20 22:59:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752049, encodeId=ccbc1e52049f9, content=<a href='/topic/show?id=6b2d5033f5' target=_blank style='color:#2F92EE;'>#complete#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5033, encryptionId=6b2d5033f5, topicName=complete)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=124036431900, createdName=lg.zhao, createdTime=Mon Feb 17 05:59:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773294, encodeId=23c61e7329455, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Thu Dec 12 06:59:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034976, encodeId=104810349e6cf, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Oct 10 10:59:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046926, encodeId=c2ae10469261f, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Thu Oct 10 10:59:00 CST 2019, time=2019-10-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1910996, encodeId=d19c1910996df, content=<a href='/topic/show?id=e6045e517dd' target=_blank style='color:#2F92EE;'>#效果分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57517, encryptionId=e6045e517dd, topicName=效果分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Nov 21 13:59:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981252, encodeId=603d198125225, content=<a href='/topic/show?id=ab0e458e711' target=_blank style='color:#2F92EE;'>#完全血运重建#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45877, encryptionId=ab0e458e711, topicName=完全血运重建)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Sep 24 09:59:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060936, encodeId=448c20609368d, content=<a href='/topic/show?id=fa39432e08b' target=_blank style='color:#2F92EE;'>#多支血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43270, encryptionId=fa39432e08b, topicName=多支血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Jan 13 01:59:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035660, encodeId=47162035660b1, content=<a href='/topic/show?id=a378432e1e7' target=_blank style='color:#2F92EE;'>#多支血管PCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43271, encryptionId=a378432e1e7, topicName=多支血管PCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Thu Feb 20 22:59:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752049, encodeId=ccbc1e52049f9, content=<a href='/topic/show?id=6b2d5033f5' target=_blank style='color:#2F92EE;'>#complete#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5033, encryptionId=6b2d5033f5, topicName=complete)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=124036431900, createdName=lg.zhao, createdTime=Mon Feb 17 05:59:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773294, encodeId=23c61e7329455, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Thu Dec 12 06:59:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034976, encodeId=104810349e6cf, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Oct 10 10:59:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046926, encodeId=c2ae10469261f, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Thu Oct 10 10:59:00 CST 2019, time=2019-10-10, status=1, ipAttribution=)]
    2020-02-17 lg.zhao
  6. [GetPortalCommentsPageByObjectIdResponse(id=1910996, encodeId=d19c1910996df, content=<a href='/topic/show?id=e6045e517dd' target=_blank style='color:#2F92EE;'>#效果分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57517, encryptionId=e6045e517dd, topicName=效果分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Nov 21 13:59:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981252, encodeId=603d198125225, content=<a href='/topic/show?id=ab0e458e711' target=_blank style='color:#2F92EE;'>#完全血运重建#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45877, encryptionId=ab0e458e711, topicName=完全血运重建)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Sep 24 09:59:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060936, encodeId=448c20609368d, content=<a href='/topic/show?id=fa39432e08b' target=_blank style='color:#2F92EE;'>#多支血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43270, encryptionId=fa39432e08b, topicName=多支血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Jan 13 01:59:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035660, encodeId=47162035660b1, content=<a href='/topic/show?id=a378432e1e7' target=_blank style='color:#2F92EE;'>#多支血管PCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43271, encryptionId=a378432e1e7, topicName=多支血管PCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Thu Feb 20 22:59:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752049, encodeId=ccbc1e52049f9, content=<a href='/topic/show?id=6b2d5033f5' target=_blank style='color:#2F92EE;'>#complete#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5033, encryptionId=6b2d5033f5, topicName=complete)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=124036431900, createdName=lg.zhao, createdTime=Mon Feb 17 05:59:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773294, encodeId=23c61e7329455, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Thu Dec 12 06:59:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034976, encodeId=104810349e6cf, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Oct 10 10:59:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046926, encodeId=c2ae10469261f, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Thu Oct 10 10:59:00 CST 2019, time=2019-10-10, status=1, ipAttribution=)]
    2019-12-12 xuyong536
  7. [GetPortalCommentsPageByObjectIdResponse(id=1910996, encodeId=d19c1910996df, content=<a href='/topic/show?id=e6045e517dd' target=_blank style='color:#2F92EE;'>#效果分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57517, encryptionId=e6045e517dd, topicName=效果分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Nov 21 13:59:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981252, encodeId=603d198125225, content=<a href='/topic/show?id=ab0e458e711' target=_blank style='color:#2F92EE;'>#完全血运重建#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45877, encryptionId=ab0e458e711, topicName=完全血运重建)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Sep 24 09:59:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060936, encodeId=448c20609368d, content=<a href='/topic/show?id=fa39432e08b' target=_blank style='color:#2F92EE;'>#多支血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43270, encryptionId=fa39432e08b, topicName=多支血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Jan 13 01:59:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035660, encodeId=47162035660b1, content=<a href='/topic/show?id=a378432e1e7' target=_blank style='color:#2F92EE;'>#多支血管PCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43271, encryptionId=a378432e1e7, topicName=多支血管PCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Thu Feb 20 22:59:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752049, encodeId=ccbc1e52049f9, content=<a href='/topic/show?id=6b2d5033f5' target=_blank style='color:#2F92EE;'>#complete#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5033, encryptionId=6b2d5033f5, topicName=complete)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=124036431900, createdName=lg.zhao, createdTime=Mon Feb 17 05:59:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773294, encodeId=23c61e7329455, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Thu Dec 12 06:59:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034976, encodeId=104810349e6cf, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Oct 10 10:59:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046926, encodeId=c2ae10469261f, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Thu Oct 10 10:59:00 CST 2019, time=2019-10-10, status=1, ipAttribution=)]
    2019-10-10 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1910996, encodeId=d19c1910996df, content=<a href='/topic/show?id=e6045e517dd' target=_blank style='color:#2F92EE;'>#效果分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57517, encryptionId=e6045e517dd, topicName=效果分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Nov 21 13:59:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981252, encodeId=603d198125225, content=<a href='/topic/show?id=ab0e458e711' target=_blank style='color:#2F92EE;'>#完全血运重建#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45877, encryptionId=ab0e458e711, topicName=完全血运重建)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Sep 24 09:59:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060936, encodeId=448c20609368d, content=<a href='/topic/show?id=fa39432e08b' target=_blank style='color:#2F92EE;'>#多支血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43270, encryptionId=fa39432e08b, topicName=多支血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Jan 13 01:59:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035660, encodeId=47162035660b1, content=<a href='/topic/show?id=a378432e1e7' target=_blank style='color:#2F92EE;'>#多支血管PCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43271, encryptionId=a378432e1e7, topicName=多支血管PCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Thu Feb 20 22:59:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752049, encodeId=ccbc1e52049f9, content=<a href='/topic/show?id=6b2d5033f5' target=_blank style='color:#2F92EE;'>#complete#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5033, encryptionId=6b2d5033f5, topicName=complete)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=124036431900, createdName=lg.zhao, createdTime=Mon Feb 17 05:59:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773294, encodeId=23c61e7329455, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Thu Dec 12 06:59:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034976, encodeId=104810349e6cf, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Oct 10 10:59:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046926, encodeId=c2ae10469261f, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Thu Oct 10 10:59:00 CST 2019, time=2019-10-10, status=1, ipAttribution=)]
    2019-10-10 CHANGE

    疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的

    0